Cargando…

IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer

Ovarian cancer is a type of gynecological cancer with the highest mortality rate worldwide. Due to a lack of effective screening methods, most cases are diagnosed at later stages where the survival rates are poor. Thus, it is termed a ‘silent killer’ and is the most lethal of all the malignancies in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dongol, Samina, Zhang, Qing, Qiu, Chunping, Sun, Chenggong, Zhang, Zhiwei, Wu, Huan, Kong, Beihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377165/ https://www.ncbi.nlm.nih.gov/pubmed/32724358 http://dx.doi.org/10.3892/ol.2020.11664

Ejemplares similares

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

CCNG1 (Cyclin G1) regulation by mutant‐P53 via induction of Notch3 expression promotes high‐grade serous ovarian cancer (HGSOC) tumorigenesis and progression
por: Xu, Ying, et al.
Publicado: (2018)

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
por: Sun, Chenggong, et al.
Publicado: (2020)

MiR-501 promotes tumor proliferation and metastasis by targeting HOXD10 in endometrial cancer
por: Sun, Xiaomei, et al.
Publicado: (2021)

miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma
por: Dong, Ruifen, et al.
Publicado: (2014)

PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma
por: Ma, Hanlin, et al.
Publicado: (2019)

Upregulated MELK Leads to Doxorubicin Chemoresistance and M2 Macrophage Polarization via the miR-34a/JAK2/STAT3 Pathway in Uterine Leiomyosarcoma
por: Zhang, Zhiwei, et al.
Publicado: (2020)

Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review
por: Li, Congcong, et al.
Publicado: (2019)

HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer
por: Dou, Zhiyuan, et al.
Publicado: (2022)

Tubal Origin of “Ovarian” Low-Grade Serous Carcinoma: A Gene Expression Profile Study
por: Wang, Yiying, et al.
Publicado: (2019)

Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma
por: Dong, Ruifen, et al.
Publicado: (2016)

The Antithetic Roles of IQGAP2 and IQGAP3 in Cancers
por: Song, Fei, et al.
Publicado: (2023)

IQGAP3 Promotes EGFR-ERK Signaling and the Growth and Metastasis of Lung Cancer Cells
por: Yang, Ying, et al.
Publicado: (2014)

TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021)

Downregulation of IQGAP2 Correlates with Prostate Cancer Recurrence and Metastasis()
por: Xie, Yanyun, et al.
Publicado: (2018)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

FBLN5 is targeted by microRNA-27a-3p and suppresses tumorigenesis and progression in high-grade serous ovarian carcinoma
por: Li, Rongrong, et al.
Publicado: (2020)

Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma
por: Serna-Gallegos, Tasha, et al.
Publicado: (2016)

Low-Grade Ovarian Serous Adenocarcinoma with Lymph Node Metastasis in Neck
por: Chen, Shih-Lung, et al.
Publicado: (2021)

Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis
por: Li, Jie, et al.
Publicado: (2012)

Ras GTPase-Activating-Like Protein IQGAP1 (IQGAP1) Promotes Breast Cancer Proliferation and Invasion and Correlates with Poor Clinical Outcomes
por: Zeng, Fanye, et al.
Publicado: (2018)

Evaluation of the prognostic value of lymphadenectomy for low-grade serous ovarian cancer: A case-control multicenter retrospective study
por: Chen, Zhongshao, et al.
Publicado: (2022)

Identification of metastasis and prognosis-associated genes for serous ovarian cancer
por: Yang, Yijun, et al.
Publicado: (2020)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

Skin Metastasis of Low-Grade Ovarian Serous Carcinoma: A Case Report
por: Ching, Lauren M, et al.
Publicado: (2023)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
por: Chowdhury, Shrabanti, et al.
Publicado: (2023)

Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer
por: Si, Manfei, et al.
Publicado: (2019)

Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
por: Zhang, Lu, et al.
Publicado: (2021)

Targeting ARF1-IQGAP1 interaction to suppress colorectal cancer metastasis and vemurafenib resistance
por: Hu, Hui-Fang, et al.
Publicado: (2022)

No evidence for PALB2 methylation in high-grade serous ovarian cancer
por: Mikeska, Thomas, et al.
Publicado: (2013)

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
por: Yan, Shunfei, et al.
Publicado: (2017)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9c84em4c8cc04c2jugcpdgofjk